EUCTR2007-007555-14-BG
Active, not recruiting
Not Applicable
An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study toEvaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as AdjunctiveTherapy in Adults With Major Depression Associated WithBipolar I Disorder
ConditionsMajor Depression Associated With Bipolar I DisorderMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depression
DrugsNuvigil
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Major Depression Associated With Bipolar I Disorder
- Sponsor
- Cephalon, Inc.
- Enrollment
- 240
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(a) The patient has a diagnosis of Bipolar I Disorder according to the DSM\-IV\-TR
- •criteria as determined by the SCID and is currently experiencing a major depressive
- •(b) The investigator has established, by medical record documentation or by history
- •from the patient and reliable informants, that the patient has had at least 1 previous
- •manic or mixed episode, which resulted in functional impairment and was treated (or
- •should have been treated) with a mood stabilizer or antipsychotic medication.
- •(c) The patient has had no more than 6 mood episodes in the last year.
- •(d) The patient’s current major depressive episode must have started no less than
- •4 weeks and no more than 12 months prior to the screening visit.
- •(e) NOTE: The following inclusion criterion is no longer effective with the
Exclusion Criteria
- •(a) NOTE: The following exclusion criterion is replaced by exclusion criterion (cc):
- •(b) The patient has active psychotic symptoms.
- •(c) The patient has a history of an attention\-deficit/hyperactivity disorder, eating
- •disorder, and/or obsessive compulsive disorder (OCD).
- •(d) NOTE: The following exclusion criterion is replaced by exclusion criterion (dd):
- •(e) NOTE: The following exclusion criterion is replaced by exclusion criterion (ee):
- •(f) The patient has a history of stimulant\-induced mania.
- •(g) In the judgment of the investigator, the patient is at risk of imminent self\-harm.
- •(h) The patient has a history of homicidal ideation or significant aggression.
- •(i) The patient has a history of any clinically significant cutaneous drug reaction.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study toEvaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as AdjunctiveTherapy in Adults With Major Depression Associated WithBipolar I DisorderMajor Depression Associated With Bipolar I DisorderMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionEUCTR2007-007555-14-HUCephalon, Inc.240
Recruiting
Not Applicable
A 8-week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of KBL396 on improvement of Sleep quality in adults with Sleep disorders, Stress, Anxiety, and DepressioKCT0006865Kobiolabs105
Recruiting
Not Applicable
Efficacy of LTC-022 on Sleep ImprovementKCT0007750Korea Institute of Oriental Medicine40
Active, not recruiting
Not Applicable
A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti- Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents With Persistent Allergic Asthma.Persistent Allergic AsthmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2007-001959-19-SESchering-Plough Research Institute, a Division of Schering Corporation90
Active, not recruiting
Not Applicable
A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti- Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents With Persistent Allergic Asthma.Persistent Allergic AsthmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2007-001959-19-DESchering-Plough Research Institute, a Division of Schering Corporation90